Health X Platform Reports Strong Revenue Growth, Narrowed Net Loss for FY26

Consolidated Revenue: ₹1,319.27 crore
Net Profit/(Loss) after tax: ₹(1.45) crore

Reader Takeaway: Strong revenue growth and reduced consolidated loss are positives, but a subsidiary's going concern uncertainty is a key risk.

What just happened

Health X Platform Limited, formerly Sastasundar Ventures Limited, announced its audited financial results for the year ended March 31, 2026. The company reported a consolidated revenue of ₹1,319.27 crore, an increase of 18.75% from ₹1,110.95 crore in FY25. The consolidated net loss after tax narrowed significantly to ₹1.45 crore from a loss of ₹133.54 crore in the previous year.

Why this matters

The substantial growth in revenue and the drastic reduction in the consolidated net loss indicate operational improvements and a better financial footing for the group. The company also completed a ₹100 crore buy-back of shares in its subsidiary, Sastasundar Healthbuddy Limited (SHBL), increasing its holding. These developments are crucial for investor confidence and reflect the company's strategic moves.

The backstory

Health X Platform, previously known as Sastasundar Ventures, has been undergoing a transformation. The name change signifies a broader strategic direction. The company's results reflect its core business operations, particularly in the healthcare network segment.

What changes now

Investors will be watching the company's ability to sustain this revenue momentum and further reduce losses. The increased stake in SHBL could lead to better integration and financial control. The divestment of Happymate Foods Limited also streamlines operations.

Risks to watch

A significant concern highlighted is the auditor's note regarding a material uncertainty about the going concern status of its subsidiary, Genu Path Labs Limited (GPLL). The consolidated results were also impacted by exceptional items, suggesting potential volatility.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Consolidated Revenue Growth: +18.75% for FY26 compared to FY25.
• Consolidated Net Loss Reduction: From ₹133.54 crore in FY25 to ₹1.45 crore in FY26.
• Subsidiary Buy-back: ₹100 crore completed in SHBL.

What to track next

Investors should closely monitor the performance of the Healthcare Network segment, which drives revenue but remains loss-making. The resolution or management of the going concern uncertainty at Genu Path Labs Limited will be a critical factor to watch.